AF
SWTX

Amalgamated Financial’s SpringWorks Therapeutics SWTX Stock Holding History

Amalgamated Financial’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$269K Buy
+4,761
New +$272K ﹤0.01% 1775

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Amalgamated Financial's SWTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in SpringWorks Therapeutics (SWTX) in Q1 2022: 4,761 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #1775 among its holdings.

136 funds tracked by Wall St. Rank hold SWTX as of Q1 2022.

  • Amalgamated Financial held 4,761 shares of SpringWorks Therapeutics worth $269K as of Q1 2022.
  • SpringWorks Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • SpringWorks Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1775 holding.
  • 136 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.